Org 50081

Phase 3Small molecule

Merck & Co.

Org 50081 is one of 63 small molecule programs targeting Panic Disorder. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Panic DisorderActive, not recruiting

InsomniaActive, not recruiting

Panic DisorderPhase 2

Active, not recruiting

InsomniaPhase 3

Active, not recruiting

Competition

Competitive Landscape

153 competitors in Insomnia

#DrugCompanyPhaseTrials

Epidiolex

Jazz Pharmaceuticals

Phase 3

2 2

Elavil

AstraZeneca

Phase 3

1 3

Neurontin

VViatris Specialty LLC

Phase 3

7 4

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

3 5

Hetlioz

VVanda Pharmaceuticals

Phase 3

2 6

Gaboxadol

Lundbeck

Phase 3

8 7

Eplivanserin

Sanofi

Phase 3

6 8

Volinanserin

Sanofi

Phase 3

2 9

Nitrazepam

Astellas

Phase 3

1 10

MK0928, Gaboxadol

Lundbeck

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Insomnia1 trial

Fifty Two Week Extension Trial of Org 50081 (Esmirtazapine) in the Treatment of Insomnia (P05708)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00610675·346 enrolled

Single Dose1 trial

A Study to Assess the Effect of Single and Multiple Doses Org 50081 and a Single Dose of Zopiclone on Next-day Driving Ability and Psychomotor Performance in Healthy Volunteers. (P05794) (COMPLETED)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT00798395·32 enrolled

Analgesic Efficacy1 trial

A Comparison of Analgesic Efficacy Between a Single Dose of ORG 28611, Morphine, and Placebo After Dental Impaction Surgery (Study P05800)

Terminated· Merck & Co. logo

Merck & Co.·Phase 2·NCT00782951·11 enrolled

Panic Disorder1 trial

Org 25935 Versus Placebo as Augmentation to Cognitive-behavioral Therapy to Treat Panic Disorder (P05705)

Terminated· Merck & Co. logo

Merck & Co.·Phase 2·NCT00725725·46 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Org 50081. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Org 50081 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Org 50081. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Merck & Co.

Org 50081

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Insomnia1 trial

Single Dose1 trial

Analgesic Efficacy1 trial

Panic Disorder1 trial

References

Drug Info

Quick Facts

Related News